Annual Report 2021
search-label
Search
search-label
Search
Overview
Overview
Editorial
Key figures
Profile
Strategy
Business Review
Business Review
Growth driven by custom projects
Increase in profitability
Accelerated capital deployment
New capabilities in oligonucleotides
Integrated ESG management
Organizational progress
Risk management and internal audit
Employees and people development
Dividend
Outlook for 2022
Corporate Responsibility
Corporate Responsibility
ESG governance
ESG materiality assessment
Integrated ESG management
ESG agenda
Governance and Remuneration
Governance and Remuneration
Corporate Governance Report
Corporate Governance Report
Corporate Governance Report 2021
Group structure and shareholders
Capital structure
Board of Directors
Executive Committee
Compensation, shareholdings and loans
Shareholders’ participation rights
Change of control and defense measures
Auditors
Information policy
Quiet periods
Remuneration Report
Remuneration Report
Letter from the Chairman of the Remuneration and Nomination Committee
Remuneration Report 2021
Remuneration governance
Remuneration philosophy and principles
Agreements related to the compensation for Members of the Board of Directors and the Executive Committee
Compensation framework for the Board of Directors
Compensation framework for the Executive Committee
IPO Recognition Bonus
Ownership of shares and options
Other remuneration-related information under the OAEC
Report on the Audit of the Remuneration Report
Financial Report
Financial Report
Consolidated financial statements
Consolidated financial statements
Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of changes in equity
Consolidated statement of cash flows
Notes to the consolidated financial statements
Report of the statutory auditor
Three-year Financial History
Financial statements of PolyPeptide Group AG
Financial statements of PolyPeptide Group AG
Income statement of PolyPeptide Group AG
Statement of financial position of PolyPeptide Group AG
Notes to the financial statements of PolyPeptide Group AG
Report on the Audit of the Financial Statements of PolyPeptide Group AG
Definitions and reconciliations
Definitions and reconciliations
Abbreviations
Operational indicators
Alternative Financial Measures (APM)
Reconciliations
Annual Report 2021
Financial Report
8
Other financial expenses
kCHF
2021
Foreign exchange result
2,225
Total other financial expenses
2,225